Angle PLC on Friday said the results of an Eisai Co Ltd pilot study supported the capability of the Parsortix system for real-time assessment of breast cancer patient HER2 status.

The Guildford, England-based cancer research company said the phase 2 results demonstrated that patient samples were successfully processed with consistent results from two samples from each patient at a time point.

Eisai is a Tokyo-based pharmaceutical company.

Angle said: ‘This data is highly significant as it validates that Angle’s HER2 assay is capable of measuring changes in HER2 status over time, which is not possible with a tissue biopsy as it is an invasive procedure which cannot always be repeated. This information is key to utilising the assay in clinical studies to assess patient treatment response and offers the potential to identify patients likely to respond to HER2-antibody-drug conjugates.’

With the demonstration of the ability to measure HER2 circulating tumour cells status dynamically over time, Angle said it successfully completed its contract with Eisai.

Separately, Angle said developed assays androgen receptor and DNA damage response have been approved for use by Cambridge, England-based pharmaceutical company AstraZeneca PLC.

Angle said: ‘These developments put Angle in the position to be able to execute large scale clinical trials for AstraZeneca. In addition, Angle is working to progress discussions in other areas where we believe AstraZeneca could benefit from adopting circulating tumour cell analysis.’

Angle shares fell 5.2% to 9.24 pence each on Friday afternoon in London, while Eisai shares closed 0.4% lower at JP¥4,332.00 each in Japan.

Copyright 2025 Alliance News Ltd. All Rights Reserved.